Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC278 25 mg q.d. and Raltegravir 400 mg b.i.d.
Conditions
Interventions
TMC278
Raltegravir
Start Date
February 1, 2011
Completion Date
May 1, 2011
Last Updated
June 27, 2011
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT05897099
NCT06665646
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions